Liver Cancer (LC) (Project-003)

摘要-肝癌(LC)研究计划 项目负责人：斯科特·弗里德曼，医学博士和何塞普·洛韦，医学博士 肝癌(LC)计划是一个综合性的多学科计划，包含了 疾病从社区筛查到两者肝癌发生的基本机制 肝细胞癌和肝内胆管细胞癌。该计划的目标是 目的是：1)阐明慢性肝病和胆道疾病的基本机制 纤维化急剧增加了肝细胞癌和肝细胞癌的风险；2)将这些基本进展转化为新的 肝细胞癌和肝细胞癌的诊断和分子分层方法；3)检验这些新方法的有效性 对研究人员发起的早期临床概念验证试验以及随后在Pivotal进行的干预 随机研究。 从这一焦点发展出来的主题是：1)慢性肝炎的基本机制 2)肝纤维化和肝细胞癌的分子和细胞基础；2)新的模型和临床前 研究肝癌的发病机制和治疗；3)创新的临床前和临床治疗策略 肝癌(肝细胞癌和肝细胞癌)。该方案的亮点包括：a)建立综合社区 致力于在服务不足的人群中筛查慢性肝病的外展计划，与 护理新诊断的肝病；b)在患者预防管理方面的独特临床专门知识 通过肝炎治疗和肝细胞癌手术治疗慢性肝病；c)基础和翻译 正在重新定义肝癌和ICC的分子分类的研究计划；d)富有成果的肝癌组织和 为世界各地的西奈山科学家和研究人员提供独特的血清库 基因组、蛋白质组和表观遗传学数据；e)在肝细胞癌和国际刑事法院的强有力的临床试验计划，该计划领导了 美国登记参加肝细胞癌临床试验。该计划具有独特的定位，可以实现其长期目标 目标是在了解肝细胞癌和肝细胞癌的机制方面取得突破性进展，并应用这些机制 致力于开发和早期测试新颖的个性化疗法，这将改善 患有这些灾难性恶性肿瘤的患者 LC项目有24名成员，他们代表10个系和6个研究所。截至2014年7月1日， 计划成员获得了3,124,363美元的NCI和其他同行审查的癌症相关直接支持。 自2011年以来，LC方案成员发布了220份报告，其中28.6%是方案内报告和 8.2%的方案间。

ABSTRACT – LIVER CANCER (LC) RESEARCH PROGRAM Program Leaders: Scott Friedman, MD and Josep Llovet, MD The Liver Cancer (LC) Program is a comprehensive multidisciplinary program that incorporates all aspects of the disease from community screening to fundamental mechanisms of heptocarcinogenesis in both hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC). The objectives of this program are to: 1) Elucidate fundamental mechanisms underlying the basis of how chronic liver or biliary disease and fibrosis precipitously increase the risk of HCC and ICC; 2) Translate these fundamental advances into novel approaches to the diagnosis and molecular stratification of HCC and ICC; 3) Test the efficacy of these novel interventions in investigator-initiated, early clinical proof-of concept trials and subsequently in pivotal randomized studies. The themes that have developed from this focus are: 1) Basic mechanisms of chronic hepatic inflammation that lead to HCC; 2) Molecular and cellular basis of hepatic fibrosis and HCC; 2) Novel models and pre-clinical studies of HCC pathogenesis and treatment; 3) Innovative therapeutic pre-clinical and clinical strategies for liver cancer (HCC and ICC). Highlights of the program include: a) Established comprehensive community outreach programs devoted to screening for chronic liver disease among underserved populations, linked to care for newly diagnosed liver disease; b) Unique clinical expertise in the preventive management of patients with chronic liver disease through hepatitis treatments and surgical care of HCC; c) A basic and translational research program that is redefining the molecular classification of HCC and ICC; d) A fruitful HCC tissue and serum bank that provides Mount Sinai scientists and investigators throughout the world with unique sets of genomic, proteomic and epigenetic data; e) A robust clinical trials program in HCC and ICC that has led the United States in enrollment in HCC clinical trials. The program is uniquely positioned to achieve its long-term goal to generate groundbreaking advances in understanding mechanisms of HCC and ICC, and to apply these towards the development and early testing of novel, personalized therapies that will improve the outlook for patients with these catastrophic malignancies The LC program has 24 members, and they represent 10 departments and 6 institutes. As of July 1, 2014, program members were awarded $3,124,363 in NCI and other peer-reviewed cancer-related direct support. Since 2011, LC program members published 220 reports, of which 28.6% were intra-programmatic and 8.2% inter-programmatic.